Sigyn Therapeutics, INC

Sigyn Therapeutics, Inc. entered into a convertible note purchase agreement for up to $550,000 while three directors resigned due to lapsed D&O insurance.

Sigyn Therapeutics announces the retirement of its CFO, provides a business update including a letter from the CEO addressing emerging pandemic threats, and releases an investor presentation.

Sigyn Therapeutics has appointed Michael Ryan, a seasoned executive and investor, to its Board of Directors, effective January 11, 2025.

Sigyn Therapeutics has amended its corporate charter to decrease the number of authorized common stock shares to 100 million, while keeping preferred stock authorizations unchanged.

Sigyn Therapeutics exchanged 246,259 stock purchase warrants for 184,699 restricted shares of common stock, eliminating all outstanding warrants.

Sigyn Therapeutics filed an amendment to a previous 8-K report to correct an error regarding the control of sellers in a recent share issuance.

Sigyn Therapeutics is pivoting its lead therapy, Sigyn CardioDialysis, to target cardiovascular disease in ESRD patients, while reporting a reduced net loss and operating expenses for Q3 2025, despite ongoing going concern issues and increased debt.

Sigyn Therapeutics reported increased net losses and a significant cash decline in Q2 2025, raising substantial doubt about its ability to continue as a going concern, compounded by recent board and CSO resignations.

Sigyn Therapeutics reports its Q1 2025 financial results, showing a net loss but highlighting advancements in its blood purification technologies targeting infectious diseases and cancer.

Sigyn Therapeutics' Q3 2024 report details ongoing development of medical devices for cancer and infectious diseases, alongside financial results reflecting a net loss and continued investment in research and development.

Sigyn Therapeutics reports its financial results for the second quarter of 2024, highlighting ongoing research and development activities and a net loss, while also detailing its financial position and future plans.

Sigyn Therapeutics reported its first quarter 2024 results, highlighting ongoing development of its blood purification technologies and a net loss of $758,088.

Sigyn Therapeutics' 2024 annual report details the company's ongoing development of medical devices for cancer and infectious disease, including its lead candidate, Sigyn TherapyTM, and its efforts to secure additional capital.

Sigyn Therapeutics, a development-stage company, released its 2023 annual report, highlighting advancements in its blood purification technologies and financial results.

Sigyn Therapeutics plans a firm commitment public offering of common stock and warrants to fund research and development, aiming for a Nasdaq listing.

Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in SIGYN THERAPEUTICS, INC. as of December 31, 2025.

Brio Capital Master Fund Ltd. and Brio Capital Management LLC have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Sigyn Therapeutics, Inc., totaling 158,932 shares as of November 19, 2024.